Mandalo
Nov 14, 11:11 AM
$RANI
$RANI & Roche: The
$1B+ Indirect Upside 🚀
Roche holds huge indirect potential for Rani Therapeutics via its majority stake in Chugai Pharmaceutical, Rani’s
$1.085B licensing partner.
Roche has the right of first refusal to sell Chugai’s drugs outside Japan. If their oral biologic succeeds, Roche’s global reach could unlock up to
$100M in sales milestones and tiered royalties for
$RANI.
Plus, Chugai holds options on 5 extra targets, multiplying deal values. Success inside the Roche Group could spark direct Roche pipeline deals (non-dilutive cash) or make
$RANI a prime long-term buyout target.
2 replies